Form 4: Travere CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Travere Therapeutics CFO Christopher R. Cline sold 470 shares of common stock for $17.31 per share, as part of a pre-arranged 10b5-1 plan to cover tax obligations.

Summary

• Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, Inc. (TVTX), reported the sale of 470 shares of common stock.
• The transaction occurred on August 27, 2025, at a price of $17.31 per share.
• Following this sale, Mr. Cline directly beneficially owns 92,656 shares of Travere Therapeutics common stock.
• The sale was executed pursuant to a Rule 10b5-1(c) written plan adopted on May 28, 2025.
• A portion of the shares sold was specifically to cover tax obligations arising from the vesting of performance-based restricted stock units (PSUs) in May 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it is an insider sale, it was pre-planned under a 10b5-1 plan and partially for tax obligations, which are routine and mitigate any negative implications typically associated with insider selling. The transaction size is also relatively small.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on new, non-public information.
• A portion of the sale was explicitly for covering tax obligations related to vested equity, which is a common and routine reason for insider sales.

Negatives

• Insider selling, even for tax purposes, can sometimes be perceived negatively by the market, although this transaction is relatively small.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
• The sale includes additional shares to cover the tax obligation that occurred upon the vesting of performance-based restricted stock units (PSUs) that vested in May 2025.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans for tax purposes, are common in the biotechnology and pharmaceutical industries as executives manage their equity compensation and tax liabilities. Such pre-arranged plans are designed to allow insiders to sell shares without being accused of trading on material non-public information.

Stakeholder Impact

• Shareholders: Minimal impact due to the small number of shares sold and the routine nature of the transaction (pre-planned, tax-related). It does not signal a change in management's confidence in the company's long-term prospects.

Key Dates

Keywords

Travere Therapeutics, TVTX, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CFO, Equity Compensation, Biotechnology